

Phage Therapy 2016

June 2-3, 2016 - Hotel Saint James Albany, Paris, France

Scientific Agenda

7h30 Welcoming of attendees

8h55 Opening Ceremony

Day 1 – June 2, 2016

Chairs: J. Azeredo, A. Gorski, M. Witzentrath

Session 1 - Phage Therapy 2016: Recent advances, mechanistic and perspectives
25 minutes of presentation + 5 minutes of discussion

9h00 Towards an efficacious treatment: current and future strategies of clinical phage therapy
Andrzej Gorski, Polish Academy of Sciences, Poland

9h30 Bacterial biofilms, phage therapy and chronic bacterial infections - complexity, efficacy, and mystery
Stephen T. Abedon, The Ohio State University, Mansfield, USA

10h00 Phage therapy of infectious biofilms
Joana Azeredo, CEB - University of Minho, Portugal

10h30 Coffee Break & Poster Presentations

**Session 2 – Part 1: Bacteriophage, Host & Microbiota Interactions
Pharmaceutical & Clinical Developments**
Therapeutic uses of bacteriophages, endolysins & peptides to combat infections
and manage antibiotic resistance
25 minutes of presentation + 5 minutes of discussion

11h00 Phagotherapy & Microbiota: Strategic roles of phages to modulate the diversity and quality of microbiota
Marvin Edeas, President of the International Society of Microbiota, France

11h30 Microbiota coadjuvants: bacteriophages-associated reactions in the gut microbiome eubiosis maintenance
Lorenza Putignani, Children's Hospital and Research Institute, Italy

12h00 A trojan horse made of lipids - techniques for liposomal encapsulation of therapeutic bacteriophages
Anita Nieth, Albert-Ludwigs-University Freiburg, Germany

12h30 Lunch, Networking & Poster Presentations

14h00 A recipe to make superendolysins for the efficient eradication of clostridia species
Rob Meijers, European Molecular Biology Laboratory (EMBL), Germany

14h30 Bacteriophage therapy for lung infections
Martin Witzentrath, Charité - Universitätsmedizin Berlin, Germany

15h15 Coffee Break & Poster Presentations

15h45 Short Oral Presentations (*7 minutes of presentation + 3 minutes of discussion*)

Natural and engineered endolysins to kill pneumococcus and other streptococci
Pedro García González, Centro de Investigaciones Biológicas, Spain

Phage endolysin and its antibacterial activity depend on E19 and D34 amino acid residues
Maheswaran Easwaran, Chungnam National University, Korea

The Enterococcus faecalis phage PhiEf11 Amidase Endolysin
Roy Harris Stevens, Temple University, United States

Evaluation of Sb-1 and Pyo-bacteriophage activity to prevent Staphylococcus aureus biofilm formation by isothermal microcalorimetry
Mariagrazia Di Luca, Charité -Universitätsmedizin Berlin, Germany

Real-time assessment of Sb-1 and Pyo-bacteriophage activity against methicillin-resistant Staphylococcus aureus mature biofilm
Tamta Tkhalishvili, Charité -Universitätsmedizin Berlin, Germany

Combining bacteriophages and portuguese honey for biofilm control
Ana Oliveira, University of Minho, Portugal

A Proteus mirabilis phage cocktail to prevent catheter-associated urinary tract infections
Luis Melo, Centre of Biological Engineering, University of Minho, Portugal

Impact of virulent bacteriophages on vibrio cholerae infection and their use in preventing cholera
Minmin Yen, Tufts University, United States

Isolation of lytic bacteriophages against multidrug-resistant Enterococcus faecalis ST55 isolated from research macaques
Mia Lieberman, Massachusetts Institute of Technology, United States

Phage therapy of Staphylococcus pseudintermedius skin infection in dogs suffering from atopic dermatitis: a case report
Piotr Golec, Polish Academy of Sciences, Poland

The use of phenolic compounds with phage therapy
Esra Acar-Soykut, Hacettepe University, Turkey

17h35 End of the first day

20h00 Phage Therapy Dinner in Marriott Hotel Opéra
Please register directly on website to participate.



8h55 Opening of the second day

Day 2 – June 3, 2016

Chairs: S. Abedon, R. Meijers, A. Sulakvelidze

Session 2 – Part 2: Bacteriophage, Host & Microbiota Interactions Pharmaceutical & Clinical Developments Therapeutic uses of bacteriophages, endolysins & peptides to combat infections and manage antibiotic resistance

25 minutes of presentation + 5 minutes of discussion

- 9h00 Bacteriophages for improving human health: from food additives to dietary supplements
Alexander Sulakvelidze, Vice-President R&D, Intralytix, USA
- 9h30 Development of bacteriophage therapy, and infection-responsive delivery mechanisms, to combat infection and blockage of urinary catheters
Jonathan Nzakizwanayo, Queen Victoria Hospital NHS Foundation Trust, West Sussex, and University of Brighton, United Kingdom
- 10h00 Using modern tools to improve phage therapy
Ryan Honaker, Principal Scientist, Epibio, USA

10h30 Coffee Break & Poster Presentations

- 11h00 Development of novel wound dressings for infection control: Exploration of infection responsive release and prophylactic bacteriophage therapy
Diana Alves, Queen Victoria Hospital NHS Foundation Trust and University of Brighton, United Kingdom
- 11h30 A novel approach for preparation of *Staphylococcus aureus* vaccine antigens using bacteriophage lysis
John Balcarek, Immunology Laboratories, Inc., USA
- 12h00 Therapeutic uses of bacteriophages to combat infections and manage antibiotics resistance in the agri-food and biopharmaceutical industries
Nancy Tawil, Phagelux, Montréal, Canada

12h15 Lunch, Networking & Poster Presentations

Session 3 – Phage Therapy 2016: How to overcome the regulatory aspects?

- 14h00 Towards an adequate regulatory framework for bacteriophage therapy
Gilbert Verbeken, Queen Astrid Military Hospital, Belgium
- 14h30 Short Oral Presentations (*7 minutes of presentation + 3 minutes of discussion*)
- The challenges of phage therapy in dentistry
Ronen Hazan, Hebrew University, Israel
- Gene insertion in the Podoviridae phage GRCS results in osmotically sensitive instability
Jeffrey Radding, EnBiotix, United States
- Treatment with PF4 bacteriophage produced by *Pseudomonas aeruginosa* inhibits *Aspergillus fumigatus*
Paul Bollyky, Stanford University, United States
- Modification of *Escherichia coli*-bacteriophage interactions by surfactants and antibiotics *in vitro*
Pauline Deirdre Scanlan, University College Cork, Ireland
- Microencapsulation of *Clostridium difficile* specific bacteriophage using glass microcapillary devices and pH dependent controlled release for colon targeted delivery
Gurinder Vinner, Loughborough University, United Kingdom
- Engineering antigen-displayed phage as vaccines
Leondios Kostrikis, University of Cyprus, Cyprus

15h30 Coffee Break & Network Session

Production of GMP-grade bacteriophages for clinical trials
Laurent Bretaudeau, Clean Cells, France

Our perspective of phage therapy in control of pathogens in aquaculture in China
Xu Yongping, Dalian University of Technology, China

Phage therapy in aquaculture: *in vitro* and *in vivo* studies
Catarina Moreirinha, University of Aveiro, Portugal

Isolation and characterization of waterborne, lytic bacteriophage with potential for biocontrol of multidrug resistant *Klebsiella pneumoniae*
Sanjay Sangeeta Ahivale, Rayat Education Society, India

16h40 Discussion: Each speaker will answer the question "What is the future of Phage Therapy?"

17h00 Phage Therapy Awards 2016
Scientific Contribution
Industrial Contribution

17h15 End of Phage Therapy World Congress 2016

4th World Congress on Targeting Infectious Diseases

PHAGE
THERAPY 2016

PHAGE THERAPY 2016
Recent Advances & Clinical Strategies

June 2-3, 2016 • Paris • France